TGFB1 and neoplasm: Interestingly, in preclinical models, the combination of anti-TGF-β and anti-PD-L1 was shown to reduce TGF-β signaling, increase intraepithelial T cell penetration and significantly reduce the tumor size in mice with high TGF-β signaling and immune-excluded tumors [29].